ZOM - Zomedica Pharmaceuticals Corp Stock Price, Fair Value and News

0.18USD0.00 (0.00%)Delayed

Market Summary

USD0.180.00

Delayed

0.00%

ZOM Stock Price

View Fullscreen

ZOM RSI Chart

ZOM Valuation

Market Cap

176.4M

Price/Earnings (Trailing)

-4.73

Price/Sales (Trailing)

6.79

EV/EBITDA

-4.36

Price/Free Cashflow

-8.01

ZOM Price/Sales (Trailing)

ZOM Profitability

Operating Margin

67.78%

EBT Margin

-150.23%

Return on Equity

-16.09%

Return on Assets

-15.31%

Free Cashflow Yield

-12.49%

ZOM Fundamentals

ZOM Revenue

Revenue (TTM)

26.0M

Rev. Growth (Yr)

14.23%

Rev. Growth (Qtr)

-14.65%

ZOM Earnings

Earnings (TTM)

-37.3M

Earnings Growth (Yr)

-43.46%

Earnings Growth (Qtr)

59.12%

Breaking Down ZOM Revenue

Last 7 days

28.6%

Last 30 days

38.5%

Last 90 days

50%

Trailing 12 Months

-10.3%

How does ZOM drawdown profile look like?

ZOM Financial Health

Current Ratio

11.5

ZOM Investor Care

Diluted EPS (TTM)

-0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	26.0M	0	0	0
2023	20.7M	22.4M	24.0M	25.2M
2022	7.8M	11.5M	15.2M	18.9M
2021	1.1M	2.1M	3.1M	4.1M
2020	516.5K	0	274.7K	32.9K
2019	2.0M	0	1.9M	758.3K
2018	1.4M	0	1.3M	1.6M
2017	1.3M	0	1.3M	1.3M
2016	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Zomedica Pharmaceuticals Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 15, 2023	powers johnny d	bought	16,500	0.165	100,000	-
Nov 17, 2023	powers johnny d	bought	16,600	0.166	100,000	-
Nov 17, 2023	heaton larry c ii	bought	16,600	0.166	100,000	ceo
Nov 15, 2023	powers johnny d	bought	25,950	0.173	150,000	-
May 26, 2023	heaton larry c ii	bought	19,090	0.1909	100,000	ceo
May 25, 2023	powers johnny d	bought	19,340	0.1934	100,000	-
Nov 18, 2021	powers johnny d	bought	112,500	0.45	250,000	-
Jun 30, 2021	cohen robert	sold	-447,343	0.8227	-543,750	ceo
Jun 30, 2021	cohen robert	acquired	125,062	0.23	543,750	ceo

Which funds bought or sold ZOM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-58.44	-45,625	19,824	-%
May 16, 2024	B. Riley Wealth Advisors, Inc.	unchanged	-	-331	1,671	-%
May 16, 2024	Arete Wealth Advisors, LLC	sold off	-100	-9,534	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-84.56	-3,980	506	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-9.00	-55,064	108,419	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	2,391	2,391	-%
May 15, 2024	Royal Bank of Canada	reduced	-72.8	-	-	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	new	-	4,375	4,375	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	reduced	-90.62	-78,511	5,764	-%
May 15, 2024	Tyler-Stone Wealth Management	unchanged	-	-2,168	5,824	-%

Are Funds Buying or Selling ZOM?

Are funds buying ZOM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZOM

No. of Funds

Unveiling Zomedica Pharmaceuticals Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2021	rowe jeffrey m	2.2%	12,652,980	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	2.4%	13,694,000	SC 13G/A
Jan 05, 2021	sabby management, llc	2.24%	12,633,334	SC 13G/A
Jul 02, 2020	equidebt llc	2.70%	9,918,913	SC 13D/A
Jun 05, 2020	armistice capital, llc	4.99%	15,315,997	SC 13G
Jun 04, 2020	intracoastal capital, llc	5.0%	15,487,333	SC 13G
Feb 21, 2020	armistice capital, llc	4.99%	6,768,444	SC 13G
Feb 12, 2020	sabby management, llc	6.47%	8,333,334	SC 13G
Jan 24, 2020	equidebt llc	8.19%	8,845,913	SC 13D
Dec 04, 2019	solensky gerald jr	36.7%	40,250,936	SC 13D/A

Recent SEC filings of Zomedica Pharmaceuticals Corp

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 15, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 13, 2024	4	Insider Trading
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 29, 2024	ARS	ARS

Peers (Alternatives to Zomedica Pharmaceuticals Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Zomedica Pharmaceuticals Corp News

Latest updates

Zomedica Pharmaceuticals Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q1	2019Q4	2019Q3	2019Q1	2018Q4	2018Q3
Revenue	-14.7%	6,262,000	7,337,000	6,347,000	6,020,000	5,482,000	6,157,000	4,776,000	4,246,000	3,751,000	2,506,000	1,261,000	16,000	14,000	17,619	21,238	290,682	284,960	279,237	758,298	533,091	293,484
Cost Of Revenue	-5.3%	2,145,000	2,264,000	1,985,000	1,972,000	1,647,000	1,946,000	1,265,000	1,240,000	1,011,000	1,019,500	18,000	36,000	6,000	-	-	-	-	-	-	-	-
Gross Profit	-18.8%	4,117,000	5,073,000	4,362,000	4,048,000	3,835,000	4,211,000	3,511,000	3,006,000	2,740,000	3,061,000	5,000	-20,000	8,000	-	-	-	-	-	-	-	-
S&GA Expenses	256.8%	4,107,000	-2,620,000	3,328,000	9,931,000	10,429,000	-2,857,500	3,735,000	8,567,000	6,703,000	8,143,000	6,124,000	5,038,000	3,468,000	3,307,608	2,298,330	1,703,443	1,494,406	1,377,252	3,212,357	1,278,118	834,570
R&D Expenses	-42.9%	1,771,000	3,099,500	867,000	859,000	918,000	693,000	1,215,000	319,000	351,000	683,000	289,000	271,000	412,000	820,884	2,702,103	630,066	789,946	962,463	7,531,375	6,551,821	630,371
EBITDA Margin	-5.8%	-1.46	-1.38	-0.71	-0.90	-1.01	-1.00	-1.35	-1.85	-2.62	-4.94	-6.10	-8.44	-17.16	-	-	-	-	-	-	-	-
Interest Expenses	100.0%	-	-500	64,000	62,000	50,000	-	-	-	107,000	-27,554	-	6,054	55,000	40.50	-	651	-	-	6,174	-	-
Income Taxes	-136.2%	-166,000	458,500	-1,920,000	-77,000	208,000	-1,049,000	-657,000	-382,000	-278,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	57.5%	-9,326,000	-21,946,500	-2,411,000	-5,326,000	-6,177,000	-3,858,500	-5,652,000	-5,655,000	-4,215,000	-5,623,500	-6,346,000	-4,711,000	-4,037,000	-4,173,202	-4,979,975	-2,450,618	-2,857,039	-2,845,679	-11,676,908	-8,421,682	-1,910,278
EBT Margin	-5.5%	-1.50	-1.42	-0.74	-0.94	-1.03	-1.02	-1.39	-1.89	-2.67	-5.01	-6.20	-8.59	-17.49	-	-	-	-	-	-	-	-
Net Income	59.1%	-9,160,000	-22,405,000	-491,000	-5,249,000	-6,385,000	-2,809,500	-4,995,000	-5,273,000	-3,937,000	-3,290,500	-6,346,000	-4,711,000	-4,037,000	-4,173,202	-4,979,975	-2,450,618	-2,857,039	-2,845,679	-11,676,908	-8,421,682	-1,910,278
Net Income Margin	-4.8%	-1.44	-1.37	-0.62	-0.87	-0.94	-0.90	-1.15	-1.63	-2.33	-4.45	-6.20	-8.59	-17.49	-	-	-	-	-	-	-	-
Free Cashflow	-93.5%	-9,925,000	-5,130,000	-3,265,000	-3,706,000	-4,370,000	-2,587,000	-3,202,000	-4,114,000	-2,554,000	-4,953,000	-5,051,000	-1,766,000	-2,653,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-3.8%	244	253	275	275	280	280	282	275	278	280	278	280	280	66.00	57.00	33.00	5.00	4.00	7.00	9.00	6.00
Current Assets	-7.8%	92.00	100	115	140	130	124	127	195	198	200	275	277	279	64.00	53.00	30.00	2.00	2.00	4.00	7.00	3.00
Cash Equivalents	-15.5%	11.00	13.00	22.00	28.00	8.00	27.00	45.00	187	192	195	271	276	277	62.00	52.00	29.00	1.00	1.00	2.00	7.00	2.00
Inventory	-1.2%	5.00	5.00	4.00	4.00	3.00	3.00	2.00	5.00	4.00	3.00	1.00	1.00	0.00	-	-	-	-	-	-	-	-
Net PPE	131.7%	24.00	10.00	8.00	7.00	7.00	7.00	7.00	2.00	1.00	1.00	1.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Goodwill	0%	62.00	62.00	74.00	64.00	64.00	64.00	64.00	15.00	43.00	43.00	43.00	-	-	-	-	-	-	-	-	-	-
Liabilities	-10.4%	12.00	13.00	14.00	15.00	17.00	12.00	14.00	9.00	9.00	10.00	6.00	4.00	3.00	3.00	3.00	3.00	3.00	2.00	-	-	-
Current Liabilities	-11.3%	8.00	9.00	7.00	7.00	9.00	8.00	7.00	4.00	4.00	4.00	5.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	8.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	-	-	-	-	-	-	-
Shareholder's Equity	-3.4%	232	240	261	259	263	267	269	266	269	271	272	276	278	51.00	88.00	30.00	2.00	2.00	5.00	8.00	-
Retained Earnings	-5.4%	-180	-170	-148	-148	-142	-136	-133	-128	-123	-119	-116	-109	-105	-68.97	-64.80	-59.82	-54.51	-52.06	-49.20	-46.36	-43.95
Additional Paid-In Capital	3.7%	31.00	30.00	29.00	27.00	25.00	24.00	22.00	14.00	11.00	9.00	7.00	6.00	5.00	15.00	18.00	9.00	5.00	4.00	4.00	3.00	3.00
Shares Outstanding	0%	980	980	980	980	980	980	980	980	980	980	949	933	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	193	-	-	-	213	-	-	-	803	-	-	-	82.00	-	-	-	12.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-51.3%	-7,590	-5,015	-3,027	-3,676	-4,257	-2,383	-2,770	-4,046	-2,471	-4,903	-4,997	-1,738	-2,638	-2,683	-5,662	-5,720	-2,173	-1,286	-3,910	-8,436	-2,581
Share Based Compensation	-0.4%	1,101	1,105	1,668	1,725	1,765	1,439	1,919	2,492	2,041	2,589	1,438	1,782	1,283	1,177	188	136	155	-	198	-	2,341
Cashflow From Investing	246.9%	5,625	-3,829	-3,123	23,321	-14,792	-15,351	-138,886	-1,437	-206	-71,582	-201	-124	-18.00	-1.18	-613*	-	1,008	-29.93	-582	-5.48	-69.09
Cashflow From Financing	-	-	-	-	-	-	-	8.00	-	-	23.00	400	1,470	217,266	12,643	28,593	33,327	2,152	-81.00	-1.41	11,967	3,007

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ZOM Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Consolidated Statements of Operations and Comprehensive Loss
Net revenue	$ 6,262	$ 5,482
Cost of revenue	2,145	1,647
Gross profit	4,117	3,835
Expenses
General and administrative	8,625	7,013
Research and development	1,771	918
Selling and marketing	4,107	3,416
Loss from operations	(10,386)	(7,512)
Interest income	1,093	1,412
Interest expense		(50)
Gain on disposal of assets	12
Other income (loss)	84	(1)
Foreign exchange loss	(129)	(26)
Loss before income taxes	(9,326)	(6,177)
Income tax (benefit) expense	(166)	208
Net loss	(9,160)	(6,385)
Unrealized gain (loss), change in fair value of available-for-sale securities, net of tax	(11)	283
Change in foreign currency translation	(52)	3
Net loss and comprehensive loss	$ (9,223)	$ (6,099)
Weighted average number of common shares - basic (in shares)	979,949,668	979,949,668
Weighted average number of common shares - diluted (in shares)	979,949,668
Loss per share - basic (in dollars per share)	$ (0.009)	$ (0.007)
Loss per share - diluted (in dollars per share)	$ (0.009)

ZOM Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 10,939	$ 12,952
Available-for-sale securities	72,023	77,545
Trade receivables, net	1,649	1,197
Inventory, net	5,062	5,123
Prepaid expenses and deposits	1,616	2,064
Other receivables	780	1,001
Total current assets	92,069	99,882
Prepaid expenses and deposits	243	250
Property and equipment, net	23,971	22,828
Right-of-use asset	2,253	2,466
Goodwill	61,580	61,580
Intangible assets, net	54,802	55,364
Non current available-for-sale securities	7,964	10,005
Other assets	819	822
Total assets	243,701	253,197
Current liabilities
Accounts payable and accrued liabilities	6,676	7,668
Accrued income taxes	66	65
Current portion of lease obligations	847	916
Customer contract liabilities	260	276
Other current liabilities	159	107
Total current liabilities	8,008	9,032
Lease obligations	1,657	1,814
Deferred tax liabilities	955	1,138
Customer contract liabilities	279	252
Other liabilities	907	944
Total liabilities	11,806	13,180
Commitments and contingencies (Note 14)
Shareholders' equity
Unlimited common shares, no par value; 979,949,668 issued and outstanding at March 31, 2024 and December 31, 2023	380,973	380,973
Additional paid-in capital	31,030	29,929
Accumulated deficit	(180,093)	(170,933)
Accumulated comprehensive income (loss)	(15)	48
Total shareholders' equity	231,895	240,017
Total liabilities and shareholders' equity	$ 243,701	$ 253,197

About Zomedica Pharmaceuticals Corp

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform and VetGuardian, a zero-touch vital signs remote monitoring system, as well as Revo Squared imaging platform comprising diagnostic imaging products and services for use in animal health. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan.

CEO	Mr. Larry C. Heaton II
WEBSITE	zomedica.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	85

Zomedica Pharmaceuticals Corp Frequently Asked Questions

What is the ticker symbol for Zomedica Pharmaceuticals Corp? What does ZOM stand for in stocks?

ZOM is the stock ticker symbol of Zomedica Pharmaceuticals Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zomedica Pharmaceuticals Corp (ZOM)?

As of Fri May 17 2024, market cap of Zomedica Pharmaceuticals Corp is 176.39 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZOM stock?

You can check ZOM's fair value in chart for subscribers.

What is the fair value of ZOM stock?

You can check ZOM's fair value in chart for subscribers. The fair value of Zomedica Pharmaceuticals Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zomedica Pharmaceuticals Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZOM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zomedica Pharmaceuticals Corp a good stock to buy?

The fair value guage provides a quick view whether ZOM is over valued or under valued. Whether Zomedica Pharmaceuticals Corp is cheap or expensive depends on the assumptions which impact Zomedica Pharmaceuticals Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZOM.

What is Zomedica Pharmaceuticals Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ZOM's PE ratio (Price to Earnings) is -4.73 and Price to Sales (PS) ratio is 6.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZOM PE ratio will change depending on the future growth rate expectations of investors.